Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aligos Therapeutics ( (ALGS) ) has provided an update.
On January 29, 2026, Aligos Therapeutics, Inc. appointed Nikhil Aneja as its Principal Accounting Officer, succeeding Lesley Ann Calhoun in that specific role while she continues as Executive Vice President, Chief Operating Officer and Chief Financial Officer. Aneja, 49, had been the company’s Vice President of Finance since February 2024 and brings prior senior finance and controller experience from diagnostic firm CareDx, Inc., as well as biopharmaceutical companies Blade Therapeutics, Inc. and Global Blood Therapeutics, Inc., underpinned by a commerce degree from the University of Delhi and Certified Public Accountant credentials, signaling a deepening of Aligos’s financial leadership bench and potential strengthening of its accounting oversight.
The most recent analyst rating on (ALGS) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Aligos Therapeutics stock, see the ALGS Stock Forecast page.
Spark’s Take on ALGS Stock
According to Spark, TipRanks’ AI Analyst, ALGS is a Neutral.
ALGS scores low primarily due to declining revenue, persistent losses, and negative operating cash flow despite low leverage. Technical indicators are mixed but lean weak with price below key moving averages, while valuation is difficult to support because the company is unprofitable and no dividend yield is available.
To see Spark’s full report on ALGS stock, click here.
More about Aligos Therapeutics
Average Trading Volume: 77,113
Technical Sentiment Signal: Sell
Current Market Cap: $48.92M
Learn more about ALGS stock on TipRanks’ Stock Analysis page.